碱性成纤维细胞生长因子检测对多发性骨髓瘤的临床意义

Clinical significance of basic fibroblast growth factor in patients with multipal myeloma

目的探讨碱性成纤维细胞生长因子(bFGF)在多发性骨髓瘤(MM)中的表达及其临床意义。方法应用酶联免疫法(ELISA)检测41例MM不同时期的血清bFGF的水平,观察其与MM临床分期、肿瘤量分级、治疗效果和骨损评分的关系,并与正常对照组比较。结果MM患者血清中的bFGF水平(70.53±21.88)pg/L较正常人水平(22.96±7.13)pg/L明显升高(P<0.01);MMⅢ期患者的bFGF血清水平(78.14±40.52)pg/L显著高于Ⅰ期(39.28±21.53)pg/L及Ⅱ期的水平(47.05±24.87)pg/L(P<0.05),而Ⅰ、Ⅱ期之间差异无显著性(P>0.05);不同肿瘤量分级的MM患者间血清bFGF的水平有显著性差异(P<0.05);MM治疗完全缓解者血清bFGF的水平比治疗前明显降低(P<0.01),而部分缓解及未缓解者,血清bFGF的水平治疗前后比较差异无显著性差异(P>0.05);不同骨损评分组间bFGF的水平无显著性差异(P>0.05)。结论血清bFGF的检测对了解MM的疾病严重程度及疗效观察有一定临床价值。

Objective To study the expression of basic fibroblast growth factor （bFGF） and its clinical significance in muhipal myeloma （MM）. Methods Serum levels of bVGF in 41 patients with MM were measured by ELISA method and compared with those of normal controls. The associations were observed among bFGF levels,MM stages（Ⅰ- Ⅲ）, and curative effect. Results Seruln levels（70.53±21.88） of bFGF in patients with MM were higher significantly than those（22.96±7.13） in normal controls（P〈0.01）. Serum levels（78.14±40.52） of bFGF in patients with m stage were higher significantly than those（47.05±24.87） in 11 stage, and （39.28±21.53） in I stage （P〈0.05）, but the difference between I stage and 11 stage was not signifcant （P〉0.05）. The differences of bFGV levels in different tumor load were found （P〈0.05）. Serum bFGF levels in patients of CR decreased obviously after treatment （P〈0.01）, but those in PR,SD and PD changed little （P〉0.05）. No difference was found between different groups according to bone lesion scores.Conclusion Serum bFGF may be an useful item for detecting clinical features and predicting prognosis of MM patients.